Clinical Remission after Syngeneic Bone Marrow Transplantation in a Patient with AL Amyloidosis

Brief Communications1 April 1995Clinical Remission after Syngeneic Bone Marrow Transplantation in a Patient with AL AmyloidosisMarjolein van Buren, MD, Ronald J. Hene, MD, Leo F. Verdonck, MD, Fred J. Verzijlbergen, MD, and Henk M. Lokhorst, MDMarjolein van Buren, MDFrom the University Hospital Utrecht, Utrecht, the Netherlands.Search for more papers by this author, Ronald J. Hene, MDFrom the University Hospital Utrecht, Utrecht, the Netherlands.Search for more papers by this author, Leo F. Verdonck, MDFrom the University Hospital Utrecht, Utrecht, the Netherlands.Search for more papers by this author, Fred J. Verzijlbergen, MDFrom the University Hospital Utrecht, Utrecht, the Netherlands.Search for more papers by this author, and Henk M. Lokhorst, MDFrom the University Hospital Utrecht, Utrecht, the Netherlands.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-7-199504010-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Systemic amyloidosis is characterized by accumulation of an eosinophilic amorphous material. Two proteins compose the deposits, one of which is the α-glycoprotein amyloid P. The nature of the other protein depends on the underlying cause of the illness (light chains in cases of AL amyloidosis associated with monoclonal gammopathy or amyloid A in cases of AA amyloidosis associated with chronic inflammatory disease).In secondary AA amyloidosis, resorption may occur when the stimulus for amyloid formation is eliminated [1, 2]. It is generally agreed that no effective therapy exists for AL amyloidosis (formerly known as primary systemic amyloidosis), but a few ...References1. Richter GW. The resorption of amyloid under experimental conditions. Am J Pathol. 1954; 30:239-51. Google Scholar2. Lowenstein J, Gallo G. Remission of the nephrotic syndrome in renal amyloidosis. N Engl J Med. 1970; 282:128-32. Google Scholar3. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood. 1991; 77:257-62. Google Scholar4. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med. 1991; 325:1267-73. Google Scholar5. Lokhorst HM, Dekker AW. Advances in the treatment of multiple myeloma. Cancer Treat Rev. 1993; 19:113-28. Google Scholar6. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985; 8:491-8. Google Scholar7. Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet. 1988; 1:1413-8. Google Scholar8. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with Iodine-123-labelled serum amyloid P component. N Engl J Med. 1990; 323:508-13. Google Scholar Author, Article, and Disclosure InformationAuthors: Marjolein van Buren, MD; Ronald J. Hene, MD; Leo F. Verdonck, MD; Fred J. Verzijlbergen, MD; Henk M. Lokhorst, MDAffiliations: From the University Hospital Utrecht, Utrecht, the Netherlands.Corresponding Author: Henk M. Lokhorst, MD, Department of Hematology, University Hospital Utrecht (G03.647), Heidelberglaan 100, 3584 CX Utrecht, the Netherlands. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLate Onset Renal Failure and Nephrotic Syndrome after Autologous Stem Cell Transplant for AL AmyloidosisSurgical removal of amyloid-laden lymph nodes: a possible therapeutic approach in a primary systemic AL amyloidosis patient with focal lymphadenopathyHigh-Dose Therapy in AmyloidosisMarked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosisMarked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosisAmyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego)Therapy for immunoglobulin light chain amyloidosis: the new and the oldNo regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvementTreating primary systemic amyloidosis with stem cell transplantation: outcomes in renal amyloidosisToxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosisKidney and liver involvement in monoclonal light chain disordersSuccessful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantationFatal Disseminated Aspergillosis following Sequential Heart and Stem Cell Transplantation for Systemic AmyloidosisBlood stem cell transplantation as therapy for primary systemic amyloidosis (AL)Secondary and infiltrative cardiomyopathiesRestrictive cardiomyopathyReview: Amyloidogenesis—Unquestioned Answers and Unanswered QuestionsReview: Immunoglobulin Light Chain Amyloidosis—The Archetype of Structural and Pathogenic VariabilityProspects for effective treatment of AL amyloidosis?Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status reportHematopoietic Cell Transplantation for Primary Systemic Amyloidosis: What Have We LearnedAMYLOIDOSISAcute tumour lysis syndrome: a case in AL amyloidosisSystemische AL-Amyloidose: Klinischer Verlauf und Grenzen der Melphalan-TherapieCardiac amyloidosisIntermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosisPrognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patientsCombined Bilateral Submandibular and Sublingual Swelling, Macroglossus, and Carpal Tunnel Syndrome Caused by Light Chain AmyloidosisAllogeneic bone marrow transplantation for systemic AL amyloidosisThe Systemic AmyloidosesCan Deposition of Amyloid Be Prevented in Alzheimer's Disease?BIOLOGY AND THERAPY OF IMMUNOGLOBULIN DEPOSITION DISEASES1H MRS of liver and brain in a patient with AL amyloidosisAßT Amyloidogenesis: Unique, or Variation on a Systemic ThemeIncidence and Impact of Light Chain Associated (AL) Amyloidosis on the Prognosis of Patients with Multiple Myeloma Treated with Autologous TransplantationTreatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine onlyRecurrence of primary (AL) amyloidosis in a transplanted heart with four-year survivalHeart transplantation in AL amyloidosis 1 April 1995Volume 122, Issue 7Page: 508-510KeywordsAmyloidosisBlood plasmaBlood pressureBone marrowBone marrow transplantationPlasma cellsRadionuclide imagingSpleenTransplantationUrine ePublished: 15 August 2000 Issue Published: 1 April 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...